172 related articles for article (PubMed ID: 16264105)
1. Bisphosphonates in metastatic bone disease: renal safety matters.
Body JJ
Oncologist; 2005; 10 Suppl 1():1-2. PubMed ID: 16264105
[No Abstract] [Full Text] [Related]
2. Preclinical perspectives on bisphosphonate renal safety.
Body JJ; Pfister T; Bauss F
Oncologist; 2005; 10 Suppl 1():3-7. PubMed ID: 16264106
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
4. The benefits and costs of bisphosphonates.
Coleman RE
J Support Oncol; 2007; 5(10):483-4. PubMed ID: 18240670
[No Abstract] [Full Text] [Related]
5. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer.
Vassiliou V; Leotsinides M; Kalogeropoulou C; Kardamakis D
BJU Int; 2009 Aug; 104(3):417-8; author reply 418. PubMed ID: 19614659
[No Abstract] [Full Text] [Related]
6. Adverse effects of bisphosphonates: current issues.
Diel IJ; Bergner R; Grötz KA
J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
[TBL] [Abstract][Full Text] [Related]
7. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
8. [Treatment of bone metastases with bisphosphonates].
Gremaud M; Delouche D; Monnerat C
Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423
[TBL] [Abstract][Full Text] [Related]
9. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
10. [Treatments of metastases in cancer].
Gligorov J; Launay-Vacher V; Aapro M
Bull Cancer; 2012 Mar; 99(3):333-43. PubMed ID: 22133711
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for care and cure.
Body JJ
Eur J Cancer; 2009 Sep; 45 Suppl 1():396-7. PubMed ID: 19775644
[No Abstract] [Full Text] [Related]
12. Bisphosphonates as adjuvant therapy.
Shapiro CL
Clin Adv Hematol Oncol; 2009 May; 7(5):319-20. PubMed ID: 19521319
[No Abstract] [Full Text] [Related]
13. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
14. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for breast cancer: questions answered, questions remaining.
Layman R; Olson K; Van Poznak C
Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and metastatic bone disease.
Barni S; Mandalà M; Cazzaniga M; Cabiddu M; Cremonesi M
Ann Oncol; 2006 Mar; 17 Suppl 2():ii91-95. PubMed ID: 16608996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
